Medicines for Chronic lymphocytic leukaemia

What it is

Chronic lymphocytic leukaemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes and, unlike acute leukaemias, usually develops slowly over months or years. It is one of the most common types of leukaemia in adults, mainly affecting older people, and is rare in younger adults. In CLL, abnormal lymphocytes build up gradually in the blood, bone marrow, and lymph nodes. Because it develops slowly, many people with CLL have no symptoms at all when it is found — it is often picked up by chance on a blood test done for another reason. When symptoms do occur, they can include: swollen glands (lymph nodes) in the neck, armpits, or groin, usually painless; persistent tiredness; frequent or persistent infections; night sweats; unintentional weight loss; a feeling of fullness or discomfort in the tummy (if the spleen is enlarged); and, sometimes, anaemia (paleness and breathlessness) or easy bruising. A distinctive and important feature of CLL is that, because it is often slow-growing and many people have no symptoms, treatment is not always needed straight away — many people are simply monitored (an approach called "watch and wait" or active monitoring), with treatment started only if and when the CLL progresses or causes problems. This can be difficult to come to terms with, but avoids unnecessary treatment for a condition that may not cause problems for a long time. When treatment is needed, effective options are available, including targeted therapies and other treatments, and outcomes have improved. The key point is that CLL is often slow-growing and may need only monitoring, with effective treatment available when required.

How it is treated

Chronic lymphocytic leukaemia is managed by specialist haematology teams, and a central principle is that treatment is based on whether and when the CLL is causing problems — because it is often slow-growing, many people do not need treatment straight away. Diagnosis involves blood tests (which show increased numbers of the abnormal lymphocytes) and specialised tests on the cells, and sometimes other tests, which confirm the diagnosis and assess its features and stage. For many people, particularly when the CLL is not causing symptoms or problems, the approach is active monitoring ("watch and wait") — regular check-ups and blood tests without treatment, starting treatment only if the CLL progresses or causes symptoms; research shows that starting treatment early, before it is needed, does not help, so monitoring avoids unnecessary treatment and side effects. When treatment is needed — for example if there are troublesome symptoms, the blood counts are affected, or the CLL is progressing — a range of effective treatments is available, including targeted therapies (which have transformed treatment for many people), chemotherapy-based treatments, and others, chosen according to the person’s situation and the features of their CLL. Supportive care, including preventing and treating infections (people with CLL are more prone to infections), is an important part of management. Because CLL is often long-term, ongoing follow-up is part of care. The reassuring messages are that CLL is often slow-growing, that many people have no symptoms and need only monitoring rather than immediate treatment, and that when treatment is needed there are effective options — so a diagnosis of CLL, while understandably worrying, often does not mean immediate treatment, and outcomes have improved with modern therapies. Any new or worsening symptoms should be reported to the specialist team.